Denosumab, a human IgG2 monoclonal antibody and it binds to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. Increased osteoclast activity, stimulated by RANKL, is a mediator of bone pathology in solid tumors with osseous metastases. Denosumab helps in treating patients with increased bone mass in males at a higher risk for the fracture, receiving androgen deprivation therapy for the nonmetastatic prostate cancer, increased bone mass in women at high risk for the fracture receiving breast cancer's adjuvant aromatase inhibitor therapy and postmenopausal females with the osteoporosis at the higher risk for a fracture, defined as the history of the osteoporotic fracture, or multiple risk factors for the fracture. The medicine Denosumab comes in the form of single-dose vials in 60 mg to administer subcutaneously.
Denosumab 60 mg injection is readily available with multiple generic medicine suppliers in India. Ikris Pharma Network is a WHO-GDP certified supplier of pharmaceutical drugs, supplying medicines for more than 7 years.